Abstract
In vivo microdialysis and single-cell extracellular recordings were used to assess the involvement of serotonin2A (5-HT2A) and serotonin2C/2B (5-HT2C/2B) receptors in the effects induced by amphetamine and morphine on dopaminergic (DA) activity within the mesoaccumbal and nigrostriatal pathways. The increase in DA release induced by amphetamine (2 mg/kg i.p.) in the nucleus accumbens and striatum was significantly reduced by the selective 5-HT2A antagonist SR 46349B (0.5 mg/kg s.c.), but not affected by the 5-HT2C/2B antagonist SB 206553 (5 mg/kg i.p.). In contrast, the enhancement of accumbal and striatal DA output induced by morphine (2.5 mg/kg s.c.), while insensitive to SR 46349B, was significantly increased by SB 206553. Furthermore, morphine (0.1–10 mg/kg i.v.)-induced increase in DA neuron firing rate in both the ventral tegmental area and the substantia nigra pars compacta was unaffected by SR 46349B (0.1 mg/kg i.v.) but significantly potentiated by SB 206553 (0.1 mg/kg i.v.). These results show that 5-HT2A and 5-HT2C receptors regulate specifically the activation of midbrain DA neurons induced by amphetamine and morphine, respectively. This differential contribution may be related to the specific mechanism of action of the drug considered and to the neuronal circuitry involved in their effect on DA neurons. Furthermore, these results suggest that 5-HT2C receptors selectively modulate the impulse flow–dependent release of DA.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Benloucif S, Keegan MJ, Galloway MP . (1993): Serotonin-facilitated dopamine release in vivo: Pharmacological characterisation. J Pharmacol Exp Ther 265: 373–377
Bhargava HN, Villar VM, Rahmani NH, Larsen AK . (1992): Distribution of morphine in brain regions, spinal cord and serum following intravenous injection to morphine tolerant rats. Brain Res 595: 228–235
Bolander H, Kourtopoulos H, Lundberg S, Persson SA . (1983): Morphine concentrations in serum, brain and cerebrospinal fluid in the rat after intravenous administration of a single dose. J Pharm Pharmacol 35: 656–659
Bonhomme N, De Deurwaerdère P, Le Moal M, Spampinato U . (1995): Evidence for 5-HT4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: A microdialysis study in the halothane-anesthetized rat. Neuropharmacology 34: 269–279
Bunney BS, Walters JR, Roth RH, Aghajanian GK . (1973): Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185: 560–571
Caccia S, Bergami A, Fracasso C, Garattini S, Campbell B . (1995): Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. Xenobiotica 25: 1143–1150
Cadoni C, Pinna A, Russi G, Consolo S, Di Chiara G . (1995): Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: Evidence from microdialysis and Fos immunohistochemistry. Neuroscience 65: 1027–1039
Callaghan R, Riordan JR . (1993): Synthetic and natural opiates interact with P-glycoprotein in multidrug- resistant cells. J Biol Chem 268: 16059–16064
Carboni E, Acquas E, Frau R, Di Chiara G . (1989): Differential inhibitory effects of a 5-HT3 antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol 164: 515–519
De Deurwaerdère P, Spampinato U . (1999): Role of serotonin2A and serotonin2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J Neurochem 73: 1033–1042
De Deurwaerdère P, Stinus L, Spampinato U . (1998): Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: Role of 5-HT3 receptors. J Neurosci 18: 6528–6538
De Simoni MG, Dal Toso G, Froditto F, Sokola A, Algeri S . (1987): Modulation of striatal metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res 411: 81–88
Di Chiara G, Imperato A . (1988): Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274–5278
Di Chiara G, North RA . (1992): Neurobiology of opiate abuse. Trends Pharmacol Sci 13: 185–192
Di Giovanni G, De Deurwaerdère P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U . (1999): Selective blockade of serotonin2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: A combined in vivo electrophysiological and microdialysis study. Neuroscience 91: 587–597
Di Matteo V, Di Giovanni G, Esposito E . (2000): SB 242084: A selective 5-HT2C receptor antagonist. CNS Drug Reviews 6: 195–205
Duxon MS, Flanigan TP, Reavley AC, Baxter GS, Blackburn TP, Fone KCF . (1997): Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience 76: 323–329
Eberle-Wang K, Mikeladze Z, Uryu K, Chesselet M-F . (1997): Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384: 233–247
Garattini S, Samanin R . (1981): The pharmacological profile of some psychomotor stimulant drugs including chemical, neurophysiological, biochemical and toxicological aspects. In Hoffmeister F, Stille G (eds), Handbook of Experimental Pharmacology. Berlin, Springer-Verlag, pp 545–586
Gobert A, Millan MJ . (1999): Serotonin 5-HT2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38: 315–317
Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ . (2000): Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 36: 205–221
Gudelsky GA, Yamamoto BK, Nash JF . (1994): Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur J Pharmacol 264: 325–330
Gysling K, Wang RY . (1983): Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res 277: 119–127
Hurd YL, Ungerstedt U . (1989): Ca2+ dependence of the amphetamine, nomifensine, and Lu 19-005 effect on in vivo dopamine transmission. Eur J Pharmacol 166: 261–269
Hutson PH, Barton CL, Jay M, Blurton P, Burkamp F, Clarkson R, Bristow LJ . (2000): Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT2C/2B receptor antagonists: Neurochemical and behavioural studies. Neuropharmacology 39: 2318–2328
Ichikawa J, Meltzer HY . (1992): Amperozide, a novel antipsychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J Neurochem 58: 2285–2291
Ichikawa J, Meltzer HY . (1995): DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res 698: 204–208
Imperato A, Di Chiara G . (1985): Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J Neurosci 5: 297–306
Kankaanpää A, Lillsunde P, Ruotsalainen M, Ahtee L, Seppälä T . (1996): 5-HT3 receptor antagonist MDL 72222 dose-dependently attenuates cocaine- and amphetamine-induced elevations of extracellular dopamine in the nucleus accumbens and the dorsal striatum. Pharmacol Toxicol 78: 317–321
Kapur S, Remington G . (1996): Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466–476
Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas DR, Baxter GS, Forbes IT, Ham P, Blackburn TP . (1996): In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117: 427–434
Koob GF, Le Moal M . (2001): Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97–129
Letrent SP, Pollack GM, Brouwer KR, Brouwer KL . (1998): Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm Res 15: 599–605
Liégeois JF, Ichikawa J, Bonaccorso S, Meltzer HY . (2000): M100907, a 5-HT2A receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex, but inhibits that in the nucleus accumbens. Soc Neurosci Abstr 26: 390
Lucas G, Spampinato U . (2000): Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine release in the rat striatum. J Neurochem 74: 693–701
Lucas G, De Deurwaerdère P, Caccia S, Spampinato U . (2000a): The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: Opposite role of 5-HT2A and 5-HT2C receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 39: 1053–1063
Lucas G, De Deurwaerdère P, Porras G, Spampinato U . (2000b): Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated. Neuropharmacology 39: 1984–1995
Meltzer HY . (1999): The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21: 106S–115S
Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet JM, Newman-Tancredi A, Audinot V, Maurel S . (1999): Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: Importance of nucleus accumbens 5- HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11: 4419–4432
Murphey LJ, Olsen GD . (1994): Diffusion of morphine-6-beta-D-glucuronide into the neonatal guinea pig brain during drug-induced respiratory depression. J Pharmacol Exp Ther 271: 118–124
Nash JF . (1990): Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 47: 2401–2408
Ögren SO, Goldstein M . (1994): Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 11: 167–177
Paxinos G, Watson C . (1986): The rat brain in stereotaxic coordinates. New York, Academic Press
Pompeiano M, Palacios JM, Mengod G . (1994): Distribution of the serotonin 5-HT2 receptor family mRNAs: Comparison between 5-HT2A and 5-HT2C receptors. Mol Brain Res 23: 63–178
Pozzi L, Trabace L, Invernizzi R, Samanin R . (1995): Intranigral GR-113808, a selective 5-HT4 receptor antagonist, attenuates morphine-stimulated dopamine release in the rat striatum. Brain Res 692: 265–268
Schmidt CJ, Fadayel GM . (1996): Regional effects of MK-801 on dopamine release: Effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther 277: 1541–1549
Schmidt CJ, Fadayel GM, Sullivan CK, Taylor VL . (1992): 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: Studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 223: 65–74
Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ . (1995): 1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head twitches in the rat are mediated by 5-hydroxytryptamine (5-HT)2A receptors: Modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273: 101–112
Seiden LS, Sabol KE, Ricaurte GA . (1993): Amphetamine: Effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 32: 639–677
Sorensen SM . (1995): The 5-HT2A antagonist MDL 100 907 blocks dizocilpine-induced increases in the firing rate of A10 dopamine neurons. Schizophr Res 15: 21
Steward LJ, Ge J, Stowe RL, Brown DC, Bufton RK, Stokes PRA, Barnes NM . (1996): Ability of 5-HT4 receptor ligands to modulate rat striatal dopamine release in vitro or in vivo. Br J Pharmacol 117: 55–62
Svensson JO, Yue QY, Sawe J . (1995): Determination of codeine and metabolites in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr B Biomed Appl 674: 49–55
Walsh SL, Cunningham KA . (1997): Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology 130: 41–58
Wang RY . (1981): Dopaminergic neurons in the rat ventral tegmental area. I. Identification and characterization. Brain Res Rev 3: 123–140
Willins DL, Meltzer HY . (1998): Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Res 781: 291–299
Acknowledgements
This work was supported by grants from Centre National de la Recherche Scientifique and Bordeaux 2 University. The Association Pôle Aquitaine Santé-secteur Médicament is gratefully acknowledged for its financial support. We are grateful to Dr. T. Blackburn (SmithKline Beecham Pharmaceuticals, Harlow, UK) for the gift of SB 206553 and to Dr. P. Soubrié (Sanofi Recherche, Montpellier, France) for the gift of SR 46349B. The authors wish to thank Dr. G. Goodall for linguistic assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Porras, G., Di Matteo, V., Fracasso, C. et al. 5-HT2A and 5-HT2C/2B Receptor Subtypes Modulate Dopamine Release Induced in Vivo by Amphetamine and Morphine in Both the Rat Nucleus Accumbens and Striatum. Neuropsychopharmacol 26, 311–324 (2002). https://doi.org/10.1016/S0893-133X(01)00333-5
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(01)00333-5
Keywords
This article is cited by
-
International society of sports nutrition position stand: caffeine and exercise performance
Journal of the International Society of Sports Nutrition (2021)
-
Caffeine, genetic variation and anaerobic performance in male athletes: a randomized controlled trial
European Journal of Applied Physiology (2021)
-
A genetic reduction in the serotonin transporter differentially influences MDMA and heroin induced behaviours
Psychopharmacology (2018)
-
5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice
Neuropsychopharmacology (2017)
-
Effects of 5-HT1A, 5-HT2A and 5-HT2C receptor agonists and antagonists on responding for a conditioned reinforcer and its enhancement by methylphenidate
Psychopharmacology (2017)
